Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis.

ABSTRACT:

Background and aims

Whereas a beneficial effect of intravenous ferric carboxymaltose (FCM) on symptoms and exercise capacity among patients with iron deficiency and heart failure (HF) has been consistently demonstrated, the effects of treatment on clinical events remain the subject of research. This meta-analysis aimed to characterize the effects of FCM therapy on hospitalizations and mortality.

Methods

Patient-level data from randomized, placebo-controlled FCM trials including adults with HF and iron deficiency with ≥52 weeks follow-up were analysed. The co-primary efficacy endpoints were (i) composite of total/recurrent cardiovascular hospitalizations and cardiovascular death and (ii) composite of total HF hospitalizations and cardiovascular death, through 52 weeks. Key se

SUBMITTER: Ponikowski P 

PROVIDER: S-EPMC10733736 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature